Technology
Health
Biotechnology

Minerva Neurosciences

$5.15
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.26 (-4.81%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell NERV and other stocks, options, ETFs, and crypto commission-free!

About

Minerva Neurosciences, Inc Common Stock, also called Minerva Neurosciences, is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. Its product pipeline includes Roluperidone, Seltorexant, MIN-117, and MIN-301. Read More The company was founded by Rogerio Vivaldi Coelho on April 23, 2007 and is headquartered in Cambridge, MA.

Employees
13
Headquarters
Waltham, Massachusetts
Founded
2007
Market Cap
200.98M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
165.57K
High Today
$5.40
Low Today
$5.11
Open Price
$5.33
Volume
100.66K
52 Week High
$12.95
52 Week Low
$5.11

Collections

Technology
Health
Biotechnology
Medical
Biopharmaceutical
Pharmaceutical
2014 IPO
US

News

Yahoo FinanceMay 13

Minerva Neurosciences Sinks To Lowest Level In A Year On Cloudy Midstage Trial Results For Depression Drug

Shares of the microcap biotech Minerva Neurosciences Inc (NASDAQ: NERV) were pulling back to their lowest level in a year Monday following the release of a clinical trial readout.

54
Yahoo FinanceMay 7

Calculating The Fair Value Of Minerva Neurosciences, Inc. (NASDAQ:NERV)

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Does the May share price for Minerva Neurosciences, Inc. (NASDAQ:NERV) reflect what it's really worth? Today, we will estimate the stock's intrinsic value by taking the expected future cash flows and discounting them to their present value. I will use the Discounted Cash Flow (DCF) model. Don't get put off by the jargon, the math behind it is actually quite straightforward. We genera...

25
Seeking AlphaMay 6

Minerva Neurosciences, Inc. (NERV) CEO Remy Luthringer on Q1 2019 Results - Earnings Call Transcript

Minerva Neurosciences, Inc. (NASDAQ:NERV) Q1 2019 Results Conference Call May 6, 2019 8:30 AM ET Company Participants William Boni - Vice President of Investor Relations and Corporate Communications Remy Luthringer - Executive Chairman and Chief Executive Officer Rick Russell - President Geoff Race - Executive Vice President, Chief Financial Officer and Chief Business Officer Conference Call Participants Roy Buchanan - JMP Securities Joel Beatty - Citigroup Operator Welcome to the Minerva Neurosci...

14

Earnings

-$0.41
-$0.27
-$0.14
$0.00
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 1, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.